Could Moderna Be a Millionaire-Maker Stock?

Moderna (NASDAQ: MRNA) is at a crucial moment right now -- for its COVID-19 vaccine candidate, its pipeline as a whole, and its investors. The company's investigational vaccine for COVID-19 is entering phase 3 clinical trials this month. This is the key stage that could make or break the company's hopes of bringing the product to market. And for investors, the results may mean an enormous gain -- or big losses.

Is the chance of success greater than the chance of failure? Let's take a look at what Moderna has reported so far, as well as possible risks ahead.

Image source: Getty Images.

Continue reading

Source Fool.com